Damien Perriman, Chief Commercial Officer of eXoZymes and the commercial lead behind the NCTx spinout, breaks down why cell-free biomanufacturing changes the rules for scaling nature’s rare molecules. Damien explains why the team spun NCTX out as a separate commercial vehicle, what it means to successfully transfer a process to a partner manufacturer (including a milestone Cayman validation), and why NCT (n-trans-caffeoyl tyramine), a trace compound found in peppercorns and hemp seed husks, has drawn so much attention as the only known agonist of HNF4A, a metabolic “switch” tied to mitochondrial function. The conversation also covers the logic behind launching first in supplements, how to build credibility in a crowded category through safety and product consistency, how regulatory timelines shape strategy, and why industrial biotech needs to move from platform-first stories to molecule-led business cases that match real market demand.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chapters:(00:00:00) Welcome, introductions, and why tech transfer matters(00:02:10) Why eXoZymes spun out NCTX to commercialize faster(00:03:30) Cayman scale-up milestone: 99% conversion and 99.6% purity(00:05:20) What the Cayman validation proves for product delivery and partners(00:08:10) Why launch NCT in supplements first, and what GRAS enables(00:10:00) Building credibility in supplements: safety, purity, and consistency(00:12:05) What HNF4A is, and why NCT is the only known agonist(00:14:30) What’s next: more human use studies, dose regimens, and GLP-1 adjacencies(00:16:00) NCT vs GLP-1s: “metabolic restoration” and where it might fit(00:18:10) “Natural” vs safe and effective: what really matters(00:21:00) Examples of trace natural molecules scaled for human use(00:22:30) GRAS + FDA timelines: how they’re navigating regulatory reality(00:26:00) The Molecule Manifesto: why industrial biotech needs molecule-led business cases(00:31:00) How eXoZymes chooses what to work on (idea management system)(00:33:00) Vision: what success looks like in 5–10 years(00:35:00) Quickfire: NCT in ice cream, NCT as “WALL-E,” and other rapid takes(00:38:10) What people misunderstand about cell-free biomanufacturing(00:40:00) Wrap-up + post-episode reflectionLinks and Resources:eXoZymesInterview: Cayman Chemical validates eXoZymes' technology and scalabilityeXoZymes’ Cell-Free Biomanufacturing Platform Gets Positive Feedback from Cayman ChemicaleXoZymes on LinkedInDamien Perriman - new CCO129. No Cells? No Problem! eXoZymes' Michael Heltzen on the Future of Microbe-Free Biotech29. Gut Check with Stephanie Culler: Persephone’s Quest for Microbiome Breakthroughs170. There's a Bug for That: Sophia Xu on CarbonBridge's Notebook Bioreactors166. The Great Reformulation: Joshua Lachter Rethinks How We Make Everything at ScaleTopics Covered:cell-free biomanufacturing, industrial biotech, NCTx, HNF4A, metabolic switch, tech transfer, CDMO, supplements vs pharma, GRAS, purity and consistencyHave a question or comment? Message us here:Text or Call (804) 505-5553⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠⁠⁠⁠Music by: Nihilore Production by: Amplafy Media

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related